CN114945609A - O连接型n-乙酰葡糖胺化蛋白质样物质及含有其的纤维症治疗药 - Google Patents

O连接型n-乙酰葡糖胺化蛋白质样物质及含有其的纤维症治疗药 Download PDF

Info

Publication number
CN114945609A
CN114945609A CN202080078767.XA CN202080078767A CN114945609A CN 114945609 A CN114945609 A CN 114945609A CN 202080078767 A CN202080078767 A CN 202080078767A CN 114945609 A CN114945609 A CN 114945609A
Authority
CN
China
Prior art keywords
linked
acetylglucosaminylated
protein
substance
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080078767.XA
Other languages
English (en)
Chinese (zh)
Inventor
伊势裕彦
松尾早织
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somar Corp
Kyushu University NUC
Original Assignee
Somar Corp
Kyushu University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somar Corp, Kyushu University NUC filed Critical Somar Corp
Publication of CN114945609A publication Critical patent/CN114945609A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
    • C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F120/10—Esters
    • C08F120/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
    • C08F120/36—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate containing oxygen in addition to the carboxy oxygen, e.g. 2-N-morpholinoethyl (meth)acrylate or 2-isocyanatoethyl (meth)acrylate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202080078767.XA 2019-11-14 2020-11-13 O连接型n-乙酰葡糖胺化蛋白质样物质及含有其的纤维症治疗药 Pending CN114945609A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019206265 2019-11-14
JP2019-206265 2019-11-14
PCT/JP2020/042362 WO2021095828A1 (ja) 2019-11-14 2020-11-13 Ｏ結合型ｎ－アセチルグルコサミン化タンパク質様物質及びこれを含有する線維症治療薬

Publications (1)

Publication Number Publication Date
CN114945609A true CN114945609A (zh) 2022-08-26

Family

ID=75912746

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080078767.XA Pending CN114945609A (zh) 2019-11-14 2020-11-13 O连接型n-乙酰葡糖胺化蛋白质样物质及含有其的纤维症治疗药

Country Status (7)

Country Link
US (1) US20220389047A1 (https=)
EP (1) EP4059567A4 (https=)
JP (1) JP7637948B2 (https=)
KR (1) KR102949437B1 (https=)
CN (1) CN114945609A (https=)
CA (1) CA3158028A1 (https=)
WO (1) WO2021095828A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250197865A1 (en) * 2022-03-03 2025-06-19 Kyushu University, National University Corporation Pharmaceutical composition for treatment or prevention of fibrotic disease
EP4603100A1 (en) * 2022-10-14 2025-08-20 Kyushu University, National University Corporation Antifibrotic agent, pharmaceutical composition for treating fibrosis, and method for inactivating myofibroblast
WO2025216313A1 (ja) * 2024-04-12 2025-10-16 国立大学法人九州大学 共重合体、抗線維化剤、線維症治療用医薬組成物及び筋線維芽細胞を不活性化する方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004043782A (ja) * 2002-05-09 2004-02-12 Toyobo Co Ltd オリゴ糖合成用水溶性高分子プライマー
US20040116677A1 (en) * 2001-01-12 2004-06-17 Chaikof Elliot L. Glycopolymers and free radical polymerization methods
JP2006276238A (ja) * 2005-03-28 2006-10-12 Fuji Photo Film Co Ltd 光重合性組成物及び平版印刷版原版
US20140235790A1 (en) * 2011-06-10 2014-08-21 University Of Washington Through Its Center For Commercialization Carbohydrate-based compositions and methods for targeted drug delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004099271A1 (ja) * 2003-05-08 2004-11-18 Toyo Boseki Kabushiki Kaisha 糖鎖含有水溶性ポリマー化合物
JP2007518830A (ja) * 2003-12-31 2007-07-12 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ Ｎ−セチルグルコサミンを含有するオリゴマー
JP5044777B2 (ja) * 2006-05-09 2012-10-10 国立大学法人 東京医科歯科大学 細胞固定化基材被覆膜用材料
JP2011190257A (ja) 2010-02-22 2011-09-29 Oita Univ 組織線維化疾患の予防または治療剤
JP7109040B2 (ja) 2016-07-25 2022-07-29 国立大学法人金沢大学 線維化抑制剤
JP2019206265A (ja) 2018-05-29 2019-12-05 株式会社デンソー 車両用空調装置
JP7341031B2 (ja) * 2018-10-31 2023-09-08 ソマール株式会社 間葉系幹細胞の分離・選別方法、培養方法及びそれに用いる選別材料

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116677A1 (en) * 2001-01-12 2004-06-17 Chaikof Elliot L. Glycopolymers and free radical polymerization methods
JP2004043782A (ja) * 2002-05-09 2004-02-12 Toyobo Co Ltd オリゴ糖合成用水溶性高分子プライマー
JP2006276238A (ja) * 2005-03-28 2006-10-12 Fuji Photo Film Co Ltd 光重合性組成物及び平版印刷版原版
US20140235790A1 (en) * 2011-06-10 2014-08-21 University Of Washington Through Its Center For Commercialization Carbohydrate-based compositions and methods for targeted drug delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HIROHIKO ISE ET AL: ""Elucidation of GlcNAc-binding properties of type III intermediate filament proteins, using GlcNAc-bearing polymers"", GENES TO CELLS, vol. 22, no. 10, pages 900 - 917 *

Also Published As

Publication number Publication date
JP7637948B2 (ja) 2025-03-03
KR20220123383A (ko) 2022-09-06
TW202131933A (zh) 2021-09-01
JPWO2021095828A1 (https=) 2021-05-20
US20220389047A1 (en) 2022-12-08
KR102949437B1 (ko) 2026-04-08
EP4059567A1 (en) 2022-09-21
CA3158028A1 (en) 2021-05-20
WO2021095828A1 (ja) 2021-05-20
EP4059567A4 (en) 2023-11-22

Similar Documents

Publication Publication Date Title
CN114945609A (zh) O连接型n-乙酰葡糖胺化蛋白质样物质及含有其的纤维症治疗药
EA019939B1 (ru) МОДИФИЦИРОВАННЫЙ ОЛИГОМЕР ДЛЯ УМЕНЬШЕНИЯ КОЛИЧЕСТВА микроРНК В КЛЕТКЕ
EA018986B1 (ru) Соединения-антагонисты рнк для модуляции активности бета-катенина
Urbanik et al. Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice
Jasinski-Bergner et al. Adipokines regulate the expression of tumor-relevant MicroRNAs
WO2012021287A2 (en) Methods for the treatment and prevention of metabolic disorders
Koliopanos et al. Molecular aspects of carcinogenesis in pancreatic cancer
US8029980B2 (en) Identification and use of agents that modulate oncogenic transcription agent activity
AU2025226726A1 (en) Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents
US11938226B2 (en) Abiotic anti-VEGF nanoparticle
TWI917337B (zh) 氧連結型n-乙醯葡萄糖胺化類蛋白物質、及含有該氧連結型n-乙醯葡萄糖胺化類蛋白物質之纖維化症治療藥
Knoop et al. Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pancreatic cancer
CN111205299B (zh) 一种stat3抑制剂及其应用
US10555961B2 (en) Materials and methods for treating bacterial infections using C-1 gentamicin
CN111110666B (zh) 一种治疗消化道癌症的药物组合物
EP4603100A1 (en) Antifibrotic agent, pharmaceutical composition for treating fibrosis, and method for inactivating myofibroblast
CN108303552A (zh) 青藤碱对胰腺癌细胞系sw1990增殖凋亡的检测方法
Reiss Insulin-like growth factor-I receptor–a potential therapeutic target in medulloblastomas
Song et al. BMP9 suppresses TNF-α-induced inflammatory response in fibroblast-like synoviocytes through Smad pathway in rheumatoid arthritis
Pan et al. Integrated analysis reveals that miR-548ab promotes the development of obesity and T2DM
CN107988223B (zh) 一种激活PTPRO基因表达的saRNA及其在肿瘤干细胞治疗中的应用
US10688086B2 (en) Method for treating cancer with dihydropyridine calcium antagonist
Rao et al. Bone Marrow Mesenchymal Stem Cells (BMSC)-Derived MicroRNA-189 Inhibits Glioma Tumorigenesis Through Suppressing Tumor Necrosis Factor-α (TNF-α)-Mediated Nuclear Factor Kappa Light Chain Enhancer of Activated B Cells (NF-κB) Signaling Pathway
JP2024058473A (ja) 筋線維芽細胞のα－平滑筋アクチン及びコラーゲンの発現抑制剤、線維症治療用医薬組成物、並びに、ｉｎ ｖｉｔｒｏで筋線維芽細胞のα－平滑筋アクチン及びコラーゲンの産生を抑制する方法
Wang et al. Pinoresinol Diglucoside Alleviates Cardiac Fibrosis Through Inhibiting Endothelial–Mesenchymal Transition via the Transforming Growth Factor‐β1/Smads Pathway in db/db Mice

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination